<Metabolites><creation_date>2005-11-16 15:48:42 UTC</creation_date><update_date>22:02:52</update_date><version>4</version><name>3-Methoxytyramine</name><accession>HMDB0000022</accession><completion_status>In progress</completion_status><ranges><range><sex>Both</sex><age><min_age>18</min_age><max_age>64</max_age></age><ethnicity>NA</ethnicity><unit>Um</unit><min_range>0.0016</min_range><max_range>0.0029</max_range><diseases><disease>Parkinson's disease<references><reference><reference_text>Loeffler DA, LeWitt PA, DeMaggio AJ, Juneau PL, Milbury PE, Matson WR: Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid. J Neural Transm Park Dis Dement Sect. 1995;9(1):45-53.</reference_text><pubmed_id>7605589</pubmed_id></reference><reference><reference_text>Engelborghs S, Marescau B, De Deyn PP: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem Res. 2003 Aug;28(8):1145-50.</reference_text><pubmed_id>12834252</pubmed_id></reference><reference><reference_text>Cheng H, Gomes-Trolin C, Aquilonius SM, Steinberg A, Lofberg C, Ekblom J, Oreland L: Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol. 1997 Jun;145(2 Pt 1):580-5.</reference_text><pubmed_id>9217094</pubmed_id></reference><reference><reference_text>Selley ML: (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med. 1998 Jul 15</reference_text><pubmed_id>25(2):169-74.</pubmed_id></reference><reference><reference_text>Zhang W, Xie Y, Gu J, Ai S, Wang J, Yamamoto K, Jin L: Liquid chromatography with amperometric detection at a nano crystalline Ce-doped lead dioxide film modified electrode for determination of (R)-Salsolinol, (R)-N-methylsalsolinol and monoamine neurotransmitters in Parkinsonian patients' cerebrospinal fluid. Analyst. 2004 Mar;129(3):229-34. Epub 2004 Feb 6.</reference_text><pubmed_id>14978525</pubmed_id></reference><reference><reference_text>Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M: 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem. 1995 Dec;65(6):2633-8.</reference_text><pubmed_id>7595560</pubmed_id></reference><reference><reference_text>Naoi M, Maruyama W: Cell death of dopamine neurons in aging and Parkinson's disease. Mech Ageing Dev. 1999 Nov;111(2-3):175-88.</reference_text><pubmed_id>10656535</pubmed_id></reference><reference><reference_text>Moser A, Scholz J, Nobbe F, Vieregge P, Bohme V, Bamberg H: Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci. 1995 Aug;131(2):183-9.</reference_text><pubmed_id>7595645</pubmed_id></reference><reference><reference_text>Abe T, Isobe C, Murata T, Sato C, Tohgi H: Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett. 2003 Jan 16;336(2):105-8.</reference_text><pubmed_id>12499051</pubmed_id></reference><reference><reference_text>Pappert EJ, Tangney CC, Goetz CG, Ling ZD, Lipton JW, Stebbins GT, Carvey PM: Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996 Oct;47(4):1037-42.</reference_text><pubmed_id>8857741</pubmed_id></reference><reference><reference_text>LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D: Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group. Neurology. 1992 Nov;42(11):2111-7.</reference_text><pubmed_id>1436520</pubmed_id></reference><reference><reference_text>Shukla R, Rajani M, Srivastava N, Barthwal MK, Dikshit M: Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. Int J Neurosci. 2006 Dec;116(12):1391-402.</reference_text><pubmed_id>17145675</pubmed_id></reference><reference><reference_text>Miura Y: Plasma beta-phenylethylamine in Parkinson's disease. Kurume Med J. 2000</reference_text><pubmed_id>47(4):267-72.</pubmed_id></reference><reference><reference_text>Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B: Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita. 2005;41(2):189-95.</reference_text><pubmed_id>16244392</pubmed_id></reference><reference><reference_text>Ishimitsu T, Hirose S, Asahara K, Imaizumi M: The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with Parkinson's disease. Chem Pharm Bull (Tokyo). 1984 Aug;32(8):3320-2.</reference_text><pubmed_id>6518609</pubmed_id></reference><reference><reference_text>Levin J, Botzel K, Giese A, Vogeser M, Lorenzl S: Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord. 2010;29(6):553-9. doi: 10.1159/000314841. Epub 2010 Jul 3.</reference_text><pubmed_id>20606437</pubmed_id></reference><reference><reference_text>Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, Yamada M, Koumura A, Sakurai T, Kimura A, Tanaka Y, Satoh M, Inuzuka T: Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci. 2011 Apr 15;303(1-2):95-9. doi: 10.1016/j.jns.2011.01.003. Epub 2011 Feb 2.</reference_text><pubmed_id>21292280</pubmed_id></reference><reference><reference_text>Dizdar N, Kagedal B, Lindvall B: Treatment of Parkinson's disease with NADH. Acta Neurol Scand. 1994 Nov;90(5):345-7.</reference_text><pubmed_id>7887134</pubmed_id></reference><reference><reference_text>Furukawa Y, Nishi K, Mizuno Y, Narabayashi H: [Significance of CSF biopterin and neopterin in hereditary progressive dystonia with marked diurnal fluctuation (HPD)--a clue to pathogenesis]. No To Shinkei. 1995 Mar;47(3):261-8.</reference_text><pubmed_id>7669428</pubmed_id></reference><reference><reference_text>Ebinger G, Adriaenssens K: Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease. Clin Chim Acta. 1973 Nov 15;48(4):427-31.</reference_text><pubmed_id>4761590</pubmed_id></reference></references></disease><disease>Brunner Syndrome<references><reference><reference_text>Brunner HG, Nelen MR, van Zandvoort P, Abeling NG, van Gennip AH, Wolters EC, Kuiper MA, Ropers HH, van Oost BA: X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet. 1993 Jun;52(6):1032-9.</reference_text><pubmed_id>8503438</pubmed_id></reference></references></disease></diseases></range></ranges></Metabolites>